<乌鸦传媒>New Treatment for NASH; Human Milk for Preterm Infants Also in TTHealthWatch: managing gout with uric acid levels Feb 10, 2024 podcast
<乌鸦传媒>High Response Rates in Psoriasis With Oral IL-23 Inhibitor At least 75% improvement in up to 79% of patients at 16 weeks, 90% improvement in 60% Feb 07, 2024
<乌鸦传媒>Using Baseline Markers to Predict Response in Psoriatic Arthritis More biomarker research is needed, but new study is a good start Dec 13, 2023 video
<乌鸦传媒>How Do You Select Systemic Therapy for Your Psoriasis Patients? Richard Warren explains the factors he considers and what his "go-to" treatment is Dec 12, 2023 video
<乌鸦传媒>Improvements With Guselkumab in Psoriatic Arthritis Seen Across All MDA Domains Experts discuss importance of both physician- and patient-reported domains Dec 06, 2023 video
<乌鸦传媒>PsA Raises Mortality Risk, but Unevenly Some psoriatic arthritis patients more vulnerable than others in Swedish study Dec 04, 2023
<乌鸦传媒>New Data on Bimekizumab in Psoriatic Arthritis Roundtable of experts weigh in on "unprecedented" efficacy, and safety issues Nov 29, 2023 video
<乌鸦传媒>Methotrexate Tied to Greater Risks for Older Patients With CKD FDA should consider warning labels based on study results, researchers argue Nov 28, 2023
<乌鸦传媒>New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis Favorable results with TAK-279 and deucravacitinib in studies at ACR Nov 22, 2023 video
<乌鸦传媒>Novel IL-17A Blocker Continues to Impress in PsA More phase II data build case for izokibep Nov 14, 2023
<乌鸦传媒>Stelara Biosimilar OK'd With Interchangeability But patent settlement may keep new product off market until 2025 Nov 01, 2023
<乌鸦传媒>Link Between Psoriasis, Heart Disease Tracks to Coronary Microvascular Dysfunction Lower coronary flow reserve associated with severity, duration of psoriasis Sep 20, 2023
<乌鸦传媒>Tool Predicts PsA Progression From Psoriasis, No Fancy Biomarkers Needed New model estimates risk from routine clinical parameters Aug 09, 2023
<乌鸦传媒>TNF Blockers for IBD Tied to Risk for Immune-Mediated Diseases "Paradoxical" finding puzzles researchers Jul 22, 2023
<乌鸦传媒>Make the Diagnosis: What Caused this Child鈥檚 Knee Lesions? A mother brought her 7-year-old son to the doctor concerned about asymptomatic lesions that had developed on his knees over the past couple of weeks. May 24, 2023
<乌鸦传媒>High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33% Mar 21, 2023
<乌鸦传媒>Biologic Switch Revs Up Response in Plaque Psoriasis "Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug Mar 19, 2023
<乌鸦传媒>Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments Real-world data indicate most patients who fail a first biologic drug never obtain remission Feb 27, 2023
<乌鸦传媒>First TYK2 Inhibitor for Psoriasis Wins FDA Approval Deucravacitinib significantly outperformed apremilast in two randomized trials Sep 11, 2022
<乌鸦传媒>First Approved Treatment for Generalized Pustular Psoriasis Spesolimab led to complete clearance of pustules within a week in more than half of patients Sep 07, 2022
<乌鸦传媒>Study: Flares in Pustular Psoriasis Often Undertreated Drug firm hopes to bring new specific treatment to market Aug 10, 2022
<乌鸦传媒>More Bad Safety News for Xeljanz Yet another risk confirmed in postmarketing study Aug 04, 2022
<乌鸦传媒>Asian Psoriasis Patients Get Less Time With Dermatologists, Study Suggests Cross-sectional study shows Asian patients have shortest face-to-face visits Aug 03, 2022
<乌鸦传媒>Chronic, Disfiguring Facial Rash With No Itching or Pain Female patient reports low quality of life after 10 years of treatments with no response Jul 11, 2022
<乌鸦传媒>Which Biologics Stick Longest for Psoriasis? British data highlight factors affecting drug longevity Jul 06, 2022
<乌鸦传媒>Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritis Phase II results suggest drug could outperform existing agents Jun 03, 2022
<乌鸦传媒>Lance Bass' Psoriatic Arthritis "I just figured it was because of dancing," says former member of 'NSYNC May 26, 2022
<乌鸦传媒>FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Years Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% May 24, 2022
<乌鸦传媒>Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitor At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
<乌鸦传媒>Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
<乌鸦传媒>Toward More Uniform Methotrexate Dosing in Psoriasis International expert group urges common standards Mar 30, 2022
<乌鸦传媒>Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
<乌鸦传媒>Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
<乌鸦传媒>How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
<乌鸦传媒>Rates of Serious Infection Differ Among Psoriasis Therapies Low overall rate, small differences versus etanercept reference, large French study showed Jul 22, 2021
<乌鸦传媒>Target TNF or IL-12/23 in Psoriatic Arthritis? Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
<乌鸦传媒>Methotrexate Impairs COVID Vax Response Can extra vaccine doses or discontinuing drug benefit patients with immune-mediated diseases? May 25, 2021
<乌鸦传媒>Plaque Psoriasis Drug Shows Promise for Psoriatic Arthritis Monoclonal antibody targets the IL-23 p19 subunit May 20, 2021
<乌鸦传媒>For Safety, One Biologic a Winner in Psoriasis, Psoriatic Arthritis Lower hospitalization rates compared with other biologics or small molecule therapies May 19, 2021
<乌鸦传媒>Drug 'TYKs' All the Boxes in Two Plaque Psoriasis Trials Significantly higher response rates with TYK2 inhibitor deucravacitinib versus apremilast Apr 25, 2021
